Benznidazole-induced drug reaction with eosinophilia and systemic symptoms syndrome in a patient with human leucocyte antigen (HLA)-A*68.
Thais Lizondo LópezJavier Gil LianesArnau Torrent RodríguezRubén González-GarcíaMontserrat Tuset CreusVictoria Amat SamaranchDolors Soy-MunerJosé Manuel MascaróPublished in: European journal of hospital pharmacy : science and practice (2024)
Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare but severe drug hypersensitivity reaction with potentially life-threatening consequences. It is characterised by fever, extensive maculopapular exanthema, lymph node enlargement, abnormal blood cell counts, and organ-related complications. Diagnosis can be challenging due to incomplete or non-specific symptoms, and it can sometimes manifest as a purely systemic disease. Discontinuation of the causative drug is essential. Treatment may involve corticosteroids and supportive care. Genetic screening for specific markers, such as human leucocyte antigen (HLA)-A*68, A11:01, and A29:02, can help identify individuals at risk for severe reactions to benznidazole, a drug used to treat Chagas disease. This case report describes the rarity and severity of DRESS syndrome, underscoring the potential benefit of genetic screening to prevent adverse reactions in patients with Chagas disease.
Keyphrases
- case report
- drug induced
- lymph node
- endothelial cells
- adverse drug
- healthcare
- genome wide
- early onset
- emergency department
- palliative care
- squamous cell carcinoma
- oxidative stress
- induced pluripotent stem cells
- copy number
- early stage
- radiation therapy
- bone marrow
- pluripotent stem cells
- diabetic rats
- stress induced
- rectal cancer